News
IPHYF
2.250
NaN%
--
H.C. Wainwright Remains a Buy on Innate Pharma (IPHA)
TipRanks · 2d ago
Innate Pharma Maps Pivotal Path in Earnings Call
TipRanks · 09/23 00:03
BTIG Remains a Buy on Innate Pharma (IPHA)
TipRanks · 09/18 10:55
Innate Pharma Secures Sobi Partnership Cash and Extends Runway as Key Oncology Trials Advance
TipRanks · 09/17 05:42
Innate Pharma-Sobi Partnership Closes, Unlocks $75 Million and Phase 3 Lacutamab Trial
TipRanks · 09/16 20:40
Innate Pharma says previously announced partnership with Sobi now effective
TipRanks · 09/16 20:05
Innate Pharma to deliver H1 2026 business update via investor webcast
TipRanks · 09/10 05:37
Innate Pharma to Highlight Oncology Pipeline at H.C. Wainwright Investment Conference
TipRanks · 09/02 07:08
Innate Pharma to Spotlight Oncology Pipeline at H.C. Wainwright Investor Conference
TipRanks · 09/02 05:40
Innate Pharma Raises €30 Million in Private Share Placement to Fund Oncology Pipeline
TipRanks · 08/19 20:49
Innate Pharma Schedules Investor Call as Oncology Pipeline Advances
TipRanks · 08/14 10:03
Innate Pharma Raises €30 Million in Share Offering to Extend Cash Runway
TipRanks · 08/14 08:37
Innate Pharma launches €22.5m share placement to fund ADC pipeline and extend runway
TipRanks · 08/13 20:32
Leerink upgrades Innate Pharma to Outperform after lacutamab deal
TipRanks · 08/11 10:20
Innate Pharma upgraded to Outperform from Market Perform at Leerink
TipRanks · 08/11 10:15
Innate Pharma price target raised to $7 from $5 at H.C. Wainwright
TipRanks · 08/10 16:30
Innate Pharma, Sobi to enable initiation of the TELLOMAK-3 study
TipRanks · 08/10 09:30
Innate Pharma CMO Sonia Quaratino to depart, Markus Jensen to succeed
TipRanks · 08/10 09:30
Innate Pharma Secures Funding and Advances Lacutamab to Phase 3 With New CMO
TipRanks · 08/10 07:23
Innate Pharma CMO to Spotlight Cancer Pipeline at BTIG Bladder Cancer Panel
TipRanks · 07/23 05:47
More
Webull provides a variety of real-time IPHYF stock news. You can receive the latest news about Innate Pharma Marseille through multiple platforms. This information may help you make smarter investment decisions.
About IPHYF
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.